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Biochemically and pathologically, there is strong evidence for both atopic and nonatopic airway 
sensitization, hyperresponsiveness, and inflammation as a consequence of exposure to tobacco 
mainstream or sidestream smoke particulate. There is growing evidence for the relation between 
exposure to mainstream and sidestream smoke and diseases resulting from reactive oxidant 
challenge and inflammation directly as a consequence of the combined activity of neutrophils, 
macrophages, dendritic cells, eosinophils, basophils, as a humoral immunological consequence of 
sensitization, and that the metal components of the particulate play a role in adjuvant effects. As 
an end consequence, carcinogenicity is a known outcome of chronic inflammation.
Smokeless tobacco has been evaluated by the IARC as a group 1 carcinogen. Of the many harmful 
constituents in smokeless tobacco, oral tissue metallothionein gradients suggest that metals 
contribute to the toxicity from smokeless tobacco use and possibly sensitization.
This work reviews and examines work on probable contributions of toxic metals from tobacco and 
smoke to pathology observed as a consequence of smoking and the use of smokeless tobacco.
1. Metals and metalloids in tobacco
Though exposure to substances from tobacco use is obviously a complex exposure, the 
carcinogens in tobacco smoke have been classified for health risk determinations into five 
major chemical classes.1 Some of these have been carefully studied, contributing to a strong 
weight of evidence for associated health risks.2 Toxic metals and metalloids constitute one 
of the more understudied major carcinogenic chemical classes in smokeless tobacco 
products and tobacco smoke. Eight of the top forty substances in the Fowles and Dybing 
table of cancer risk indices are metals or metalloid compounds.1 In their table of non-cancer 
risk indices for individual chemical constituents of mainstream cigarette smoke based on a 
single cigarette per day, three of the top eight listed for respiratory effect health risk, 
cadmium, hexavalent chromium, and nickel, were metals. Another metalloid, silicon in the 
form of silicates, poses serious health risks by inhalation, but limited data is available, likely 
due to analytical difficulties.
Metals and metalloids in smoke from biomass combustion including tobacco are generally 
considered to be present in ionic form, but may also occur in a gaseous elemental form, as is 
the case for mercury.3 Whether a tobacco product is consumed by smoking or in a 
smokeless form, the exposure to toxic metals is directly related to the concentration in the 
tobacco leaf, assuming no metal containing additives are included during manufacture.4–6 
The soil (including any amendments to the soil such as sludge, fertilizers, or irrigation with 
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polluted water) has been shown to be the predominant source of characteristic metal content 
found in tobacco and varies with geographical area.7–17 Amendments that lower the soil pH 
increase metal availability.8,10,13 Therefore if soil or its amendments have elevated metal 
concentrations or low pH, this will be reflected in elevated metals concentrations in tobacco 
crops grown on the soil.
As an example of soil management and effects on tobacco metals concentrations, close to 
80% of cropland soil in China was deficient in phosphate in 1980 - less than 10 milligrams 
of phosphate per kilogram of soil. Over the last 30 years, the Chinese government put 
policies in place to encourage the use of phosphate fertilizer to remediate the phosphate-
depleted soil. As a result, the average phosphate content in the soil has nearly tripled.18 
While this increases crop production, phosphate, an excellent chelator of many metal ions, 
adds metals to the soil also. Fertilization with animal waste acidifies the soil and elevates 
concentrations from excreted toxic metals. These soil management practices, while founded 
on good agricultural practices, have increased levels of phosphate and metals in runoff 
wastewater sometimes used for irrigation as a consequence of excessive application. In 
unrelated studies, arsenic, cadmium, and lead concentrations in Chinese cigarette tobacco 
have been found to be two to three times higher than levels found in Canadian cigarette 
tobacco.6
Higher levels of metals in the tobacco likely result in increased exposure for smokers or 
consumers of smokeless tobacco products. Relating specific chemical intake or “dose” to a 
particular harmful outcome is difficult due to the chemically complex nature of tobacco 
products. For single chemical exposures it is much easier to relate specific chemical doses to 
a particular response or outcome. A dose-response relationship, a mathematical construct 
useful to characterize the effect on an organism from exposure is often used to estimate 
harm potential. The characterization may be on the basis of different levels of exposure for a 
specific duration of time. If the time duration is relatively short, it may be described as an 
acute exposure. At a constant level of exposure, the dose-response depends on the duration 
of exposure. If the duration of exposure is relatively long or repeated frequently, it may be 
described as a chronic exposure. The biological response to exposure to a stressor depends 
on both the level and duration of exposure.
Two examples of biological responses to both acute and chronic exposures to toxic metals as 
a consequence of tobacco use, and as a consequence of occupational exposures are included 
in discussions of metals in the next section. In many cases, the consequences of short 
duration low level chronic exposures would not be expected to result in the pathological 
manifestations of an acute high level exposure, nor to the same degree of intensity. Thus, 
some consequences of acute occupational metal exposures discussed may not be observed as 
a consequence of lower chronic occupational exposures or chronic exposures from tobacco 
products. Other factors, however, that should be considered when evaluating the effects of 
chronic toxic metals exposure are bioaccumulation and sensitization. Although a single 
acute exposure, or low level chronic exposure may not result in immediate clinical effects, 
bioaccumulation may result in an increase in pathological consequences over time. Several 
metals and metalloids described below accumulate in lung and other tissues as a 
consequence of tobacco use. Further, if one is sensitized to a metal, then a biological 
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response will often subsequently be observed at much lower concentrations. Several metals 
described below are potent sensitizers; and some of these also accumulate in the body. 
While Inhalation Minimum Risk Levels (MRL), when available, have been summarized in 
Table 4, the American Toxic Substances and Disease Registry cautions on the use of MRLs 
when sensitization is a consideration. See the Table 4 caption.
The extent to which consumption of a particular tobacco product confers toxic metal 
exposure risks is an important question. Many factors must be considered such as the form 
of the product, where and under what conditions the agricultural sources of the product were 
cultivated, manufacturing treatments prior to marketing, the manner in which the product is 
consumed, and individual differences in consumption habits. Smokeless tobacco products 
are consumed in a much different manner than cigarette tobacco or other smoking products. 
Whether the product is consumed in a smokeless form or by smoking influences overall 
exposure and subsequent associated health risks. In addition, people who are subjected to 
exposure in the form of secondhand smoke are often at increased risk. The pathology and 
associated health risks associated with tobacco products arise from the cumulative exposure 
to all toxic, irritant, and carcinogenic substances that are biologically available. However, 
since toxicology and carcinogenesis are complex processes, different toxic substances are 
usually approached for study individually. This review summarizes available evidence 
related to selected health risks from metals or metalloid exposures that are classified by the 
International Agency for Research on Cancer (IARC) carcinogens, or metals which show 
evidence of sensitization or inflammation as a consequence of exposure in smokeless 
tobacco products or from cigarette smoke.
2. Selected Health Impacts from Metals and Biological Availability from 
Tobacco
Exposure to a given toxic metal or metalloid is limited by the concentration of the metal in 
the tobacco product. Therefore concentrations of metals and metalloids in the tobacco itself 
are relevant and proportional to the amount transported in smoke from combustion 
products.4–6 Analytical data for metals in tobacco or smoke for estimation of dose, or as 
dose-limiting values summarized here is from the most recent sources at the time of writing 
with an effort to consider evidence of analytical accuracy with a few exceptions where well-
validated data is sparse. Thus, the data on individual metals or metalloids listed 
alphabetically should not be construed as an exhaustive or comprehensive compilation. 
Inhalation Minimum Risk Levels (MRL) where available from ATSDR are included in 
Table 4.
Aluminum
Occupational inhalation exposures to aluminum in some chemical forms have been reported 
to result in chronic bronchitis, aluminum pneumoconioses, pulmonary fibroses, 
granulomatoses, anaphylactic responses, and neurotoxicity.19–23 Aluminum has been shown 
to be absorbed and reach the brain via olfactory pathways,24 and accumulates in lungs of 
smokers. Aluminum has been reported at significantly higher concentrations in the exhaled 
breath condensate of study subjects with Chronic Obstructive Pulmonary Disorder (COPD), 
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than that of nonsmoking healthy control subjects. When the COPD patients were subdivided 
into smokers vs. ex-smokers and nonsmokers, smokers had significantly higher 
concentrations of aluminum in exhaled breath condensate.25
Selected results from analysis of aluminum concentrations in smokeless tobacco and 
cigarette filler tobacco are summarized in Tables 1 and 2.
Arsenic
Arsenic is an IARC group 1 human carcinogen.26 Arsenic is readily absorbed as a 
consequence of oral or inhalation exposure and has been associated with toxicities related to 
and causing vasoconstriction and other cardiovascular effects,27 lung cancers, dermal 
cancers, and dermal sensitization.28 Correlations between arsenic exposure and 
biomonitoring levels are difficult, since arsenic is rapidly cleared from the blood with a half-
life of three to four hours.28
Selected results from analysis of arsenic concentrations in smokeless tobacco and cigarette 
tobacco are summarized in Tables 1 and 2. Selected results from analysis of arsenic 
concentrations in cigarette smoke particulate obtained using ISO and Health Canada Intense 
smoking regimens are summarized in Table 3.
Barium
Barium is a dermal chemical irritant; and may cause dermal lesions.29 When ingested orally 
or inhaled, barium can cause tachycardia, hypertension, and a benign granulomatous 
pneumoconiosis.30
Selected results from analysis of barium concentrations in smokeless tobacco cigarette 
tobacco are summarized in Tables 1 and 2. One study using artificial saliva in an attempt to 
better mimic human uptake of extractable barium in smokeless tobacco showed that barium 
was readily extracted.31 Though extraction efficiencies from smokeless tobacco shown in 
parentheses in Table 1 were low in some cases, the net mass of artificial saliva-extractable 
barium was the highest of all the metals examined.31
Beryllium
Beryllium is an IARC group 1 human carcinogen,32 and is known to cause inflammation 
and sensitization reactions as a result of dermal or inhalation exposure. Pulmonary exposure 
may result in the granulomatous and fibrotic lung disease, berylliosis, or chronic beryllium 
disease, which further presents with interstitial edema, and acute obstructive pathology.33
Because of its low concentration in tobacco and smoke particulate relative to other metals 
and associated analytical challenges, beryllium in tobacco smoke is generally below 
analytical method detection limits. Beryllium concentrations in tobacco smoke were 
reported below respective method detection limits.34 Thus, it is difficult at present to assess 
the significance to health consequences of beryllium in tobacco smoke. Beryllium ion in 
poorly soluble forms, such as the oxide, accumulates in lung up to a concentration plateau 
when equilibrium is reached between deposition and clearance during continuous exposure. 
About half is rapidly cleared predominantly via the lymphatic system. The more slowly 
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cleared portion may accumulate in the lungs for a longer period and be involved in toxic 
challenge. In rats, females exhibited less efficient clearance and earlier morbidity and 
mortality from exposure.35 Rhoades and Sanders36 reported a 400 day half life for clearance 
of beryllium oxide from rat lung. In a dose study of beryllium sensitization and chronic 
beryllium disease in a beryllium machining plant, 20 of 235 individuals who had lifetime 
weighted average airborne exposures between 0.024 μg/m3 and 0.6 μg/m3, well below the 2 
μg/m3 occupational exposure limit intended to prevent chronic beryllium disease, 
nevertheless were found to be sensitized to beryllium.37 Once sensitization is detectable, 
progression of the obstructive disease often occurs at a rate depending on level of 
exposure.38 Thus inflammation and sensitization from low beryllium exposure as a result of 
smoking or use of smokeless tobacco use may be a concern even at low concentrations.
Selected results from analysis of beryllium concentrations in smokeless tobacco and 
cigarette tobacco are summarized in Tables 1 and 2. Beryllium was extracted from 
smokeless tobacco using artificial saliva and showed a measurable extractable beryllium 
concentration for only one U.S. brand of moist snuff and three samples of leaf tobacco sold 
for chewing. The other four had less than 0.003 μg/g extractable beryllium (the method limit 
of detection).31 Extraction efficiencies for beryllium were higher than for barium.
Cadmium
Cadmium is an IARC group 1 human carcinogen32 and is highly toxic to kidney, bone, and 
the nervous, respiratory, and circulatory systems.39 Blood cadmium levels are strongly 
associated with increased prevalence of Peripheral Artery Disease.40 Associations between 
increased urine cadmium concentration and periodontal disease,41 between cadmium 
exposure, smoking, and pancreatic cancer,42 and between cadmium exposure, smoking, and 
diabetes have been reported.43
Cadmium is typically among the highest concentrations of the toxic and carcinogenic metals 
found in tobacco. Cadmium has a biological half-life of 13.6 to 23.5 years.44 Because of its 
long biological half-life, cadmium bioaccumulates as a consequence of smoking. Increases 
in cadmium levels in lung tissue have been correlated with smoking history.45 Cadmium 
concentrations have been reported to be significantly higher in four of five lobes of smokers' 
lungs examined by Tsuchiyama et al.46 The mean cadmium concentration was higher in the 
fifth lobe of smokers than of nonsmokers, but the differences were not significant. Elevated 
cadmium levels in body fat,47 blood,48–50 urine,48,51,52 and in amniotic fluid of women,49,53 
indicate systemic absorption from the lungs.
Pulmonary exposure to nebulized cadmium compounds has been demonstrated to induce 
emphysema54 and pulmonary interstitial fibrosis.23,55 Cadmium has been reported at higher 
concentrations in the exhaled breath condensate of study subjects with Chronic Obstructive 
Pulmonary Disorder (COPD), than that of the nonsmoking healthy control subjects and in 
current control smokers vs. control nonsmokers. When the COPD patients were subdivided 
into smokers vs. ex-smokers and nonsmokers, smokers had significantly higher 
concentrations of cadmium in exhaled breath condensate. Cadmium in exhaled breath 
condensate positively correlated with smoking history in pack-years.25
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Selected results from analysis of cadmium concentrations in smokeless tobacco and cigarette 
tobacco are summarized in Tables 1 and 2. One study using artificial saliva in an attempt to 
better mimic human uptake of extractable cadmium in smokeless tobacco showed that 
cadmium was readily extracted.31 The results of the extractions including extraction 
efficiencies shown in parentheses are shown in Table 1. Also included in Table 1 are 
extraction efficiencies from Maier et al. using phosphate buffer or 0.001 M chelating agents 
DHHA, EDTA, and DTPA in phosphate buffer. Selected results from analysis of cadmium 
concentrations in cigarette smoke particulate obtained using ISO and Health Canada Intense 
smoking regimens are summarized in Table 3.
Normalization of the cadmium deliveries from U.S. cigarettes to tar delivery eliminated all 
significant differences between smoke delivery categories.56 Delivery differences could 
therefore be attributed to differences in filter ventilation levels. Cadmium transported in 
smoke particulate matter from twenty-one counterfeits of two popular U.S. brands seized in 
2003 in six different length and nominal smoke delivery categories were from 2.0 to 6.5 
times higher than the authentic U.S. brands purchased in 2003; and the differences were all 
significant.57 Stephens et al. reported significantly higher cadmium concentrations in 
tobacco from counterfeit cigarettes seized in the U.K.58
Chromium
Chromium (VI) is known to cause oral and epidermal allergic contact dermatitis as well as 
pulmonary sensitization.59–64 Chromium (VI) is found in cigarette smoke and ash.65 There 
are limited reports that elevated chromium (III) exposure may also result in contact allergic 
sensitization.62 While it is generally presumed that most of the chromium in tobacco is in 
the chromium (III) oxidation state,65 manganese oxides are known to oxidize chromium (III) 
to chromium (VI) in soil and solutions.66 Manganese in one or more oxidation states is 
transported in smoke particulate, therefore it is possible that this oxidation could also occur 
in saliva or in smoke moist particulate droplets, and on moist surfaces in the lungs to some 
degree.
Accumulation of chromium in lung tissue has been correlated with smoking history, 
confirming that chromium, in some form, reaches the lung.45 Chromium concentrations 
have been reported to be significantly higher in all five lobes of smokers' lungs than in 
nonsmokers' lungs.46 However, it is not clear in what proportions chromium (III) and 
chromium (VI) accumulate. Data to date have been based on analyses of chromium (III) and 
chromium (VI) by difference in two methods, in cigarette ash, or before and after reduction. 
Chromium in tobacco smoke is therefore a health concern, but it is currently difficult to 
assess the full impact of oral, pulmonary, and systemic chromium exposure with regard to 
health consequences in view of the insufficiently available data to directly and reliably 
characterize the concentrations and biological consequences associated with the oxidation 
state of chromium.
Selected results from analysis of chromium concentrations in smokeless tobacco and 
cigarette tobacco are summarized in Tables 1 and 2.
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Copper is nutritionally required at low concentrations, but inhaled copper is a respiratory 
irritant, causes alveolar migration of macrophages, eosinophilia, formation of histiocytic and 
noncaseating granulomas containing inclusions of copper, pulmonary fibrosis, and formation 
of fibrohyaline nodules very similar to those found in silicosis as a consequence of 
occupational exposures.67 Copper was shown to more strongly induce pulmonary 
inflammation than other transition metals on a per mass basis when tested in rats.68 Copper 
is an active oxidation-reduction (redox) metal, as is iron. Since the redox chemistries of iron 
and copper have similar toxicological consequences, discussion of the relevance of redox 
activity follow in the discussion of iron.
Although copper has been reported at significantly lower concentrations in the exhaled 
breath condensate of study subjects with Chronic Obstructive Pulmonary Disorder (COPD) 
than that of the nonsmoking healthy control subjects,25 copper has been determined at 
significantly higher concentrations in blood of smokers than of nonsmokers.69
Selected results from analysis of copper concentrations in smokeless tobacco and cigarette 
tobacco are summarized in Tables 1 and 2. Extraction efficiencies using phosphate buffer or 
0.001 M chelating agents DHHA, EDTA, and DTPA in phosphate buffer70 are also included 
in Table 1.
Iron
Iron (II) inhalation was shown to cause pulmonary inflammation in rats, though not as 
strongly as copper and nickel.68 Due to its redox chemistry, iron is also known to catalyze 
highly reactive hydroxyl radical formation from superoxide ion and hydrogen peroxide by 
the two-step Fenton reaction,71 as does copper. As a consequence, inhaled iron and copper 
could contribute to free radical-induced lung injury.
Iron has been reported at significantly lower concentrations in the exhaled breath condensate 
of study subjects with COPD compared to nonsmoking healthy control subjects,25 but 
Padmavathi et al. determined iron at significantly higher concentrations in serum of chronic 
smokers than of nonsmokers72 in agreement with other rat and human studies.73 Presence of 
trace iron with silicates has been shown to augment pulmonary inflammatory response to 
silica exposure.74–77 Selected results from analysis of iron concentrations in smokeless 
tobacco and cigarette tobacco are summarized in Tables 1 and 2.
Lead
Lead is classified as an IARC group 2A probable human carcinogen.78 Lead accumulates 
over the lifetime in bone. Even at adult blood lead concentrations that are considered to be 
acceptably low (< 10 μg/dL), associations between lead concentration and elevations in 
systemic blood pressure and decrements in glomerular filtration rate have been reported.79 
Increased lead accumulation in the blood and in amniotic fluid of women,49 and in the cord 
blood of newborn babies80,81 has been associated with smoking. Elevated blood lead levels 
in U.S. children have also been associated with second-hand smoke exposure.82
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Lead concentrations have also been reported to be significantly higher in four of five lobes 
of smokers' lungs,46 indicating accumulation in smokers' lungs also. Lead has been reported 
at higher concentrations in the exhaled breath condensate of study subjects with COPD, than 
that of the nonsmoking control subjects and in current normal smokers vs. nonsmokers. 
Further subdivision of COPD patients comparing smokers vs. ex-smokers and nonsmokers 
also showed that smokers had significantly higher concentrations of lead in exhaled breath 
condensate.25
Selected results from analysis of lead concentrations in smokeless tobacco and cigarette 
tobacco are summarized in Tables 1 and 2. One study using artificial saliva in an attempt to 
better mimic human uptake of extractable lead in smokeless tobacco showed that lead was 
not readily extracted.31 The results of the extractions including extraction efficiencies shown 
in parentheses are shown in Table 1. Selected results from analysis of lead concentrations in 
cigarette smoke particulate obtained using ISO and Health Canada Intense smoking 
regimens are summarized in Table 3. Normalization of the lead deliveries to tar eliminated 
all significant differences between smoke delivery categories. Delivery differences could 
therefore be attributed to differences in filter ventilation levels. Lead concentrations 
transported in identical varieties purchased in 2004 were not significantly different from the 
comparable 2002 varieties among the brands tested, with only one exception.56 However, 
the lead in mainstream smoke particulate matter from twenty-one counterfeits of two 
popular U.S. brands seized in 2003 in six different length and nominal smoke delivery 
categories were from 3.0 to 13.8 times higher than the authentic U.S. brands purchased in 
2003; and the differences were all significant.57 Stephens et al. reported significantly higher 
lead concentrations in tobacco from counterfeit cigarettes seized in the U.K.58
Manganese
Manganese (II) complexes have been studied in tobacco.83 Manganese (III) and (IV) exists 
in complex-bound forms such as plant photosystem II proteins.84 The (III), (IV), (V), (VI), 
and (VII) oxidation states are generally more toxic in uncomplexed forms. The capacity of 
manganese oxides to oxidize chromium (III) to chromium (VI)66 adds the oxidation-
reduction dimension to potentiation of chromium toxicity. U.S. Environmental Protection 
Agency reports stated that compounds of manganese were suspected of inducing or 
exacerbating asthma.85 Manganese (II) has been shown to cause pulmonary inflammation in 
rats, though not as strongly as copper or nickel.68 Selected results from analysis of 
manganese concentrations in smokeless tobacco and cigarette tobacco are summarized in 
Tables 1 and 2.
Mercury
Mercury is highly systemically toxic in a number of forms.86 Mercury from dental amalgam 
is associated with sensitization and intraoral lichenoid lesions in some cases.87,88 Metallic 
mercury and mercury compounds were included among air pollutant compounds of concern 
due to toxicity and as respiratory tract irritants that may exacerbate asthma.85 Selected 
results from analysis of mercury concentrations in smokeless tobacco and cigarette tobacco 
are summarized in Tables 1 and 2. Selected results from analysis of mercury concentrations 
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in cigarette smoke particulate obtained using ISO and Health Canada Intense smoking 
regimens are summarized in Table 3.
Nickel and Cobalt
Although both cobalt and nickel are nutritionally required at trace concentrations, nickel is 
an IARC group 1 carcinogen,89 and cobalt is an IARC group 2b possible human 
carcinogen.90,91 Though cobalt is neither considered as potent a carcinogen as nickel, nor 
generally present in tobacco at concentrations as high as those of nickel, they are related 
immunologically in causing metal sensitizations including epidermal and oral allergic 
contact sensitizations, contact dermatitis inflammations, pulmonary inflammations and 
pneumoconioses, and asthmatic conditions.23,60,63,64,92,93 Once sensitized to one of these 
metals, immunological cross sensitization to the other is often observed, since they share an 
endothelial inflammatory activation pathway.23,94,95 Though lipopolysaccharide is the 
natural ligand for human Toll-like receptor 4 (TLR4) that is involved in inflammatory 
response, nickel (II) has been specifically identified as directly activating proinflammatory 
signal cascades by binding to this receptor.96 Dolovich et al. determined an additional 
mechanism by which nickel sensitization-induced inflammation occurred: binding to the 
copper binding site of human serum albumin, and causing sensitization to the resulting 
metal-protein complex.97 Cobalt was also able to bind to serum albumin and to the antibody 
complex. Shirakawa et al. also discovered cobalt-conjugated human serum albumin-specific 
IgE in patients with occupational hard metal asthma.98 Like many of the other metals, nickel 
bioaccumulates. Nickel concentrations have been reported to be significantly higher in all 
five lobes of smokers' lungs compared to nonsmokers' lungs.46 Nickel has been reported as 
present in significantly higher concentrations in placenta samples of smokers than in 
placenta of non-smokers,53 affirming systemic absorption from the lungs.
Selected results from analysis of cobalt and nickel concentrations in smokeless tobacco and 
cigarette tobacco are summarized in Tables 1 and 2. One study using artificial saliva in an 
attempt to better mimic human uptake of extractable cobalt and nickel in smokeless tobacco 
showed that cobalt and nickel were readily extracted.31 The results of the extractions 
including extraction efficiencies shown in parentheses are shown in Table 1. Also included 
in Table 1 are extraction efficiencies for nickel using phosphate buffer or 0.001 M chelating 
agents DHHA, EDTA, and DTPA in phosphate buffer.70 Stephens et al. (2005) reported 
nickel concentrations from 1.1 to 2.7 μg/g in tobacco from legally purchased cigarettes 
available in the U.K. (Table 2). They reported nickel concentrations and from 0.9 to 9.2 μg/g 
in tobacco filler from counterfeit cigarettes (Table 2).58
Silicon
Silicon is taken up from soil by plants in the available silicate form, generally in the form of 
kaolin (aluminum silicate). Silicates accumulate in higher plants and have structural and 
stress resistance roles in plant physiology.99 The concentrations of silicates in plants exceed 
solubility and form biogenic “phytoliths”,100 which are predominantly silica (SiO2) 
polymers.
Pappas Page 9









Silica inhaled in the form of quartz or cristobalite (different forms of SiO2) is an IARC 
group 1 human carcinogen.101 When tobacco smoke is inhaled, silicates in the forms of 
metal silicates and silica (SiO2) particles are transported. Aluminum silicate particles are 
found in smokers' lungs at elevated concentrations.102 Lynn et al. described bronchoalveolar 
lavage containing 1011 macrophages with prominent lysosomes containing amorphous 
carbon, round dense particles, and needle-like crystals of aluminum silicate from a 
pulmonary patient for whom no source except smoking was found as an explanation for the 
foreign substances.103 Choux et al. described the composition of numerous silicate particles 
in the alveolar macrophages of a patient with tobacco-associated pulmonary fibrosis as 
fiber-, needle-, or laminar-like inclusions that varied from 0.2 to 2 μm in size, the size range 
of the major proportion of the total mass of particulate from cigarette smoke.104 Aluminum 
and silicon were the major elemental components. Iron and sulfur were additional 
components. Brody and Craighead described lysosomal “smokers inclusions” in interstitial 
and alveolar macrophages and lymphocytes as predominantly aluminum silicate with plate-
like structures, and suggested their involvement in pulmonary fibrosis.105 Heckman and 
Lehman described lung epithelial cells of rats that had received chronic tobacco smoke 
exposure as containing elongated cytoplasmic inclusions. They stated that macrophages had 
similar larger inclusions composed of silicon, aluminum, phosphorous, iron and sulfur.106 
Thus silicate metal-bearing particulate is a major component of the particulate found in 
smokers' lung. As described above, presence of trace iron has been shown to augment 
formation of reactive oxygen species in pulmonary inflammatory response to silica 
exposure.74–77 Nonsmokers may also acquire environmental silicate exposure to a much 
lower extent unless exposed occupationally.107 Data on silicon (silicates) in tobacco or 
tobacco smoke is sparse, likely because of analytical difficulties.
3. Transfer of Metals in Mainstream, Sidestream, and Secondhand Tobacco 
Smoke Basic smoke chemistry
The temperature of tobacco burning at the tip of a cigarette may reach over 900°C. Smoke 
inhaled into the mouth (mainstream smoke) is approximately 30°C; and sidestream smoke 
leaving the burning tip falls below 100°C about 10 centimeters from the tip.108 Thus a 
burning cigarette tip is hot enough to volatilize many metal ions, or to cause them to react 
with other substances to form volatile compounds and complexes. As a consequence, some 
of the metals may reside in the gas phase. By the time the smoke is inhaled or rises in a 
plume from the cigarette as sidestream smoke, most of the metal ions condense with other 
materials forming particles that comprise much of the particulate matter of the smoke 
aerosol.108 Mainstream cigarette smoke, when inhaled, transports many substances through 
the mouth, throat, and into the lungs, where a substantial portion of the particulate matter 
and volatiles are deposited. Many of these substances are rapidly absorbed through the 
lungs, transfer efficiently to the blood stream, and are distributed quickly through the 
circulatory system. Other smoke constituents including 60% to 80% of particulate are 
retained, accumulate in the lungs, and gradually partition between lung airways, tissue, and 
circulatory or lymphatic absorption.109
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Cigarette smoke is a major source of exposure to ultrafine and fine particulate matter. Most 
of the particulate mass occurs in particles with diameters between 0.1 and 1.3 μm, the lower 
half of the fine particle diameter range.110,111 Though ultrafine particulate (<0.1 μm) from 
tobacco smoke is not the fraction with the greatest mass, the small size facilitates deeper 
penetration into the lung, more rapid uptake into cells, and into circulation.112,113 Geiser et 
al. found that after an exposure of rat lung to a 4–5 μg dose of insoluble ultrafine TiO2 
particles, the particles were found widely distributed on luminal sides of airways and alveoli, 
in all tissue compartments and cells, and within capillaries. They concluded that these 
ultrafine particles were not taken up by endocytic processes, but by diffusion.114 Ferin and 
Oberdörster115 stated earlier that particles not phagocytized by alveolar macrophages were 
taken up by endocytosis in alveolar epithelial cells. They stated that an increasing dose in 
terms of particle number promoted greater interstitialization, associated with inflammation. 
Whether the systemic dispersion of ultrafine particles was due to diffusion or transcytosis, it 
is apparent that particle dose, size, and composition impact the response. Smaller particle 
size increases the potential for oxidative stress per unit mass of particulate matter as a 
consequence of the greater surface area to mass ratio. Ultrafine or nanosized ultrafine 
particulate may cause greater neutrophil inflammatory response per unit mass.112,113
Approaches to estimate metals exposures from smoke
Once a metal or metalloid is absorbed in the lung, its biological fate determines much of the 
resulting health impact. Some metals such as cadmium and chromium may accumulate and 
remain predominantly in the lung tissue for a very long biological lifetime.45
Since pulmonary lavage and biopsy procedures are invasive, analyses of metal 
concentrations in smoke are used to estimate relative potentials for exposures to metals from 
cigarettes. Most published reports of metals concentrations in cigarette smoke used 
standardized machine smoking regimens based on ISO conditions (35mL puff volume, 2s 
puff duration, 60 s puff frequency). Data obtained using Intense smoking conditions (50mL 
puff volume, 2s puff duration, 30 s puff frequency with any ventilation holes blocked) is 
very appropriate for relative estimations of exposure potentials, given the intentional or 
unintentional blocking of ventilation holes with smokers' fingers,116 but data derived from 
use of the intense regimen is sparse. These regimens have been developed as approximations 
to a “typical” individual smoking pattern, though individual differences vary widely. 
Though smoking machine methods are better suited for comparing physical design 
characteristics or brand to brand differences, they do provide useful information on the 
presence and typical concentrations of metals in mainstream smoke.
4. Toxicological ramifications of tobacco smoke exposure
Adjuvant effect in sensitization, and inflammation caused by tobacco smoke inhalation
Biochemically and pathologically, there is strong evidence for both atopic and nonatopic 
airway sensitization, hyperresponsiveness, and inflammation as a consequence of exposure 
to tobacco mainstream or sidestream smoke particulate. There is growing evidence for the 
relation between exposure to mainstream and sidestream smoke and diseases resulting from 
Pappas Page 11









reactive oxidant challenge and inflammation directly as a consequence of the combined 
activity of neutrophils, macrophages, dendritic cells, eosinophils, basophils, as a humoral 
immunological consequence of sensitization, and that the metal components of the 
particulate play a role in adjuvant effects.
Tobacco smoke exposure has been shown to increase sensitization to organic and biological 
allergens. Nielsen et al. discussed the evidence favoring a sensitization role in occupational 
exposures to organic and biological substances using smoking as a model for airborne 
adjuvant effects. They concluded that smoking exhibited an adjuvant effect on the immune 
response to many potential biological, organic, and inorganic allergens, including platinum 
metal salts. Development of platinum-specific IgE and sensitization studied with skin prick 
tests was described.117 Arnson et al. discussed data showing that cigarette smoke was able to 
augment the production of pro-inflammatory cytokines such as TNF-α, IL-1, IL-6, IL-8, 
GM-CSF (all of which are also associated with sensitization to various substances), and to 
decrease the levels of interferon-γ (IFN-γ) and anti-inflammatory cytokine IL-10. Data 
showing that exposure to tobacco smoke leads to elevated IgE concentrations, to the 
subsequent development of atopic diseases and asthma, and to the known activation of 
macrophage and dendritic cell activity was also discussed.118 Both alveolar macrophages 
and dendritic cells may act as antigen-presenting cells that could have induced the IgE 
production.
Rumold et al.119 studied the sensitization of immunological low responder (C57BL/6) mice 
exposed to nebulized ovalbumin with or without concurrent inhalation of sidestream smoke. 
They found that sidestream smoke exposure induced sensitization to ovalbumin, evident 
from antigen-specific IgE compared to no detectable sensitization in those exposed to 
ovalbumin alone. Upon rechallenge, significantly increased levels of proinflammatory GM-
CSF and IL-2 cytokines could be detected in bronchoalveolar lavage even in the secondhand 
smoke alone-exposed animals.119
Goel et al. reported significantly higher serum IgE concentrations in smokers compared to 
former smokers and non-smokers in a study of 70 individuals. Absolute eosinophil counts 
from smokers and former smokers were not significantly different between the two groups, 
but both were significantly higher than those of nonsmokers. No significant airways 
obstruction was determined in non-smokers, but both smokers and former smokers had 
significantly greater obstruction than non-smokers. Former smokers showed significantly 
greater airways obstruction than current smokers.120
Regland et al. reported a strong relation between smoking and nickel contact allergy in both 
atopic and nonatopic individuals, though more prevalent in nonatopic smokers than in atopic 
smokers.121 In a cross-sectional study, Linneberg et al. found with patch test that general 
contact allergy to any of 23 chemical allergens, specific nickel contact allergy, and allergic 
nickel contact dermatitis were significantly and dose-dependently associated with smoking 
history of 15 pack years or more. Linneberg et al. also stated that smoking-associated 
contact allergy was observed among both atopic and nonatopic subjects; and that no 
significant association between skin prick test and contact allergy was observed. In these 
cases, sensitized T cell-mediated cellular immunity may have played a major role.63
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Immune cells and metallo-particles: mixed immunological activation
Sanders et al. showed that NiO [nickel (II) oxide] and Cr2O3 [chromium (III) oxide] dust 
particles were predominantly found engulfed by alveolar macrophages in hamsters. A 
smaller fraction was in the alveolar lumen itself. A still smaller fraction was found in 
neutrophils of hamsters that were also exposed to cigarette smoke and in the type I but not 
the type II alveolar epithelium. The authors pointed out that neutrophils were rarely 
observed in alveolar lumens of hamsters exposed to only NiO, and that observed 
vacuolization was a more common finding in macrophages from animals which were also 
exposed to cigarette smoke.122
Gilmour et al. demonstrated that intratracheal exposure of rats to either high transition 
metal-containing residual oil fly ash particulate or its major constituent metals alone (nickel 
or vanadium) caused significant pulmonary inflammation. Increased protein levels and TNF-
α, monocyte and granulocyte migration to the site were observed. They reported that the 
predominantly metals-containing particulate exhibited an adjuvant effect on sensitization to 
dust mite with IgE production, as several authors cited earlier observed with tobacco smoke 
particulate inhalation.123 In a separate study, Lambert et al. showed that the enhanced 
sensitization was mediated by the soluble metal constituents of the particulate. Specifically, 
increased eosinophil numbers in bronchoalveolar lavage were observed in response to either 
particulate or iron exposure alone during sensitization. Dust mite-specific IgE was higher in 
groups exposed to particulate, or to nickel or vanadium alone.124
Costa and Dreher compared dose response of rats to which oil or coal fly ash particulate was 
administered intratracheally on the basis of either total particulate mass or on the basis of 
bioavailable transition metal mass. Their results indicated that it was the lung dose of 
bioavailable transition metal and not total instilled particulate mass that was the primary 
determinant for acute inflammatory response.125
Walczak-Drzewiecka et al. observed allergen-mediated activation of cultured nonsensitized 
mouse mast cells with only 2% to 5% degranulation in response to 10−7 M aluminum 
chloride, nickel (II) sulfate, strontium or cadmium chloride alone. When dinitrophenyl-
human serum albumin-sensitized mast cells were exposed to antigen alone, approximately 
11% degranulation was observed. Together with aluminum chloride, antigen exposure 
response more than doubled with 23% degranulation. Similar results were observed for 
nickel (II) sulfate.126
Both airway epithelial cells and alveolar macrophages may phagocytize irritant particles and 
as a result of the encounters, synthesize pro-inflammatory cytokines that induce airway 
inflammation and contribute to airway lesions in asthma and chronic obstructive pulmonary 
disorder.127 Goto et al. showed that in response to PM10 particulate, alveolar macrophages 
released macrophage colony-stimulating factor (M-CSF), macrophage inflammatory 
protein-1ß, GM-CSF, IL-6, TNF-α, IL-1ß, IL-8, and monocyte chemotactic protein 
(MCP-1).128 Monocytes, which may differentiate into macrophages or dendritic cells, are 
the predominant inflammatory cells that are recruited from the bone marrow to the alveoli 
following particulate matter exposure, especially exposure to particulate matter with high 
metal concentrations.
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Carter et al.129 also studied the inflammatory effects of 5 to 200 μg/mL environmental 
particulate matter with low organic and high metals concentrations (2.6% carbon and 
hydrogen by mass, 18.8% vanadium, 3.75% nickel, 3.55% iron, remainder miscellaneous 
elements) on normal human bronchial epithelial cells and found transcription induction and 
expression of pro-inflammatory cytokines TNF-alpha, IL-6, and IL-8. Cytokine production 
was inhibited by inclusion of the metal chelator deferoxamine. They concluded that metals 
present in the particulate matter are predominantly responsible for inducing production and 
release of inflammatory mediators by the respiratory tract.
Schaumann et al.130 noted metals-dependent differences in the effects of instillation of 
suspensions of environmentally relevant concentrations of only 100 μg particulate matter 
(PM2.5) collected from two different German cities into contralateral lung segments of 12 
healthy volunteers. Instillations from both cities increased the numbers of leukocytes in 
bronchoalveolar lavage after 24 hours, but the particulate matter from only one of the two 
cities, which contained higher concentrations of transition metals, also induced significant 
increases in monocyte influx, TNF-α, and IL-6 in lavage fluid and increased oxidant radical 
generation by the lavage cells. It was apparent that the higher concentration of transition 
metals in the PM2.5 from the latter city was responsible for the increased inflammation.
The mRNA for Toll-Like receptors TLR2 and TLR4 mRNA, discussed earlier in relation to 
inflammation, nickel, and cobalt binding, were respectively upregulated and unaltered, but 
surface expression of the gene products fell significantly and precipitously when cultured 
human dendritic cells were exposed to predominantly metal-containing ambient particulate 
at even the lowest concentrations of 0.1 μg/mL, while pro-inflammatory cytokine (GM-CSF, 
IL-6, IL-12, TNF-α) mRNA transcription and cytokine secretion increased substantially. 
Ambient particulate matter directed a nonclassic dendritic cell activation and mixed Th1/
Th2-like cytokine response by naïve CD4+ T cells. There was no speculation on whether the 
surface expression decrease for TLR2 and TLR4 was due to internalization with bound 
ligands (since as discussed earlier, nickel and cobalt bind and activate TLR4). Allergenicity 
of various metals and the support from the data for an adjuvant-like effect of metals in 
particulate on dendritic cells (which are antigen-presenting cells) was discussed.131
Rossi et al. reported that the responses of exposure of healthy or asthmatic mice to an acute 
(10 mg/m3) dose of airborne fine TiO2 particulate or silica-coated nanofine TiO2 particulate 
resulted in significant suppression of lymphocyte and eosinophil numbers in lavage and 
suppressed allergic/asthmatic response in ovalbumin sensitized mice.132 In response to an 
even higher diesel exhaust particulate dose, suppression of both innate and Th1 cell-
mediated responses to Listeria monocytogenes (an intracellular pathogen), suppression of 
IL-1β TNF-α, and IL-12, but increased IL-10 (anti-inflammatory cytokine) production by 
alveolar macrophages was observed in rats.133 They also observed downregulation of T cell 
responses such as suppression of secretion of IL-2, IL-10, and IFN-γ on various days post-
infection. Misson et al. observed an immediate inflammatory response after acute tracheal 
instillation of suspended MnO2 or silica. An “alternative (M2) activation” of murine 
macrophages presented in the early stages of fibrosis, but returned to classical M1 activation 
with time and as the fibrosis progressed.134 M2 activation phenotypes would be less 
resistant to intracellular pathogens.
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The summary of support for metals involvement in inflammation, sensitization, and immune 
suppression in this section was based on environmental particulate data because of the 
greater volume of literature on this particulate and due to the high mass fraction of the 
transition metal components. This is directly relevant to tobacco smoke particulate, because 
as participants in the 2001 National Urban Air Toxics Research Center workshop were 
informed, the main components of environmental tobacco smoke are also urban air 
toxics.135 Specific examples of relations between the contribution of tobacco smoke 
particulate metals with inflammation and sensitization are discussed below.
Toxicological consequences of metallo-particle inhalation specifically from tobacco 
smoke
Lin et al. studied obstructive lung disorder in 6726 subjects with data obtained from the 
National Health Assessment Nutrition Examination Survey (III) published by the U.S. 
Centers for Disease Control and Prevention after exclusions for various conditions. They 
found adjusted odds of approximately 1.9 for increased prevalence of obstructive lung 
disorder among those in the lowest zinc-intake tertile versus those in the highest tertile 
regardless of smoking status. They reported relative mean odds ratios for obstructive lung 
disease of 1.00 for never smokers, 2.60 and 3.37 for former smokers, 4.38 and 7.66 for 
active smokers in two different regression models. After adjusting for creatinine-corrected 
urine cadmium concentrations, the effect of smoking on lung disorder risk decreased 
considerably, suggesting that at least the cadmium intake alone from tobacco smoke was a 
comparable factor for obstructive lung disorder as smoking itself. Their implication was that 
metals in tobacco smoke, and specifically cadmium, are major contributors to the risk of 
obstructive lung disorders.136
Using X-ray Microanalysis, Terzakis described particulate compounds from peripheral lung 
in 18 cases – 2 nonsmokers and 1 cigar smoker as autopsy-obtained controls, and 15 with 
peripheral lung carcinomas (10 of whom were smokers). Of the 15 cancer cases, all cancers 
were associated with fibrosis. The subjects had neither received occupational exposures nor 
exposures to asbestos, and no observable asbestos bodies in lung tissue examined. Elevated 
carbonaceous pigment appeared in fibrotic tissue vicinal to tumors as did particulate 
material in the carcinoma cases compared to the control group. The particulate material was 
composed of silicon, aluminum, phosphorus, vanadium, chromium, iron, nickel, copper, 
arsenic, cadmium, lead, etc. In the 18 total cases examined, silicon was the prominent 
element in particles. Kaolinite, silica, and other silicates in the particles were present.137
Though extensive large aluminum silicate inclusions in alveolar macrophages of smokers 
were described in earlier citations,103–106 Becker et al. stated that neutrophils exhibited a 
stronger oxidative response to silicate exposure, whereas alveolar macrophages exhibited 
stronger response to oil fly ash particulate (higher in transition metals, lower in silicate,138 
and consistent with the data from Sanders et al.122 and suggested that wide variation in 
macrophage response to metal oxide or silica was likely associated with particle 
composition. They concluded that reactive oxidant activation as a consequence of various 
sources of particulate matter is cell specific, and that the inflamed lung is more susceptible 
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to harm from a broader range of particulate size and composition because of the oxidant 
stress posed.138
In response to silica exposure, Beamer and Holian found that large numbers of granulocytes 
were recruited to the lungs of C57Bl6 mice,139 consistent with the findings of Becker et 
al.138 They also noted that the alveolar macrophage to dendritic cell ratio was noticeably 
altered in favor of dendritic cells in response to silica compared to unexposed mice, though a 
subset population of inflammatory CD11bhigh alveolar macrophages appeared. Beamer and 
Holian suggested silica-induced apoptosis of alveolar macrophages as one explanation of 
their decrease in numbers with time subsequent to silica exposure,139 though their 
observation of macrophage migration to the interstitium (and other observations115) is an 
additional explanation. The appearance of a new macrophage phenotype, together with other 
data, indicated recruitment of this population from peripheral sources. In response to silica 
exposure, portions of both macrophages and dendritic cells migrated to the interstitium, but 
only the dendritic cells increased the number of CD3+ and CD4+ lymphocytes, suggesting 
the dendritic cells as the major antigen presenting cells in this case.145 Though tobacco 
smoke transports silicates to the lungs, it has been shown that smoke decreases the number 
of mouse dendritic cells in the lungs.140 Hornung et al. showed that either silica or 
aluminum salt crystals were ingested by phagocytosis into peripheral blood mononuclear 
cells.141 The phagocytosis of the crystals led to destabilization and rupture of the 
phagosome-lysosomal compartment, releasing contents into the cell cytosol. Lysosomal 
destabilization triggered activation of the NALP3 inflammasome and induced release of 
inflammatory cytokine Il-1β. Dostert et al. demonstrated NADPH oxidase activity upon 
silica particle phagocytosis, which implies generation of reactive oxygen species. They 
reported that NALP3 inflammasome activation was triggered by the reactive oxygen 
species.142 These findings are a important links between aluminum silicates and silica and 
inflammatory response.
TNF-α and IL-1β inflammatory cytokine signals induced by exposure to tobacco smoke, to 
particulate, and to metals may also indirectly stimulate fibrotic response to inflammation. 
TNF-α stimulates production of TGF-β1. TGF-β1 in turn increases production of connective 
tissue growth factor (CTGF). Both TGF-β1 and CTGF are major stimulators of collagen 
production.143,144 IL-1β stimulates macrophages to produce matrix metalloproteinase-9145 
and increases expression of PDGF-AA and of platelet-derived growth factor alpha receptor 
(PDGFRα) on lung fibroblasts. This hormone system is involved in tissue metal-induced 
airway fibrosis146 as the combination of metalloproteinase-catalyzed destruction of tissue 
and production of fibrous connective tissue by fibroblasts is involved in tissue remodeling 
observed in COPD development.
Ghio et al. found that after exposure of rats to cigarette smoke, lavage concentrations of iron 
and ferritin, serum ferritin, and nonheme iron concentrations in lung and liver increased.73 
The excessive lung particulate iron burden as a consequence of smoking was examined by 
bronchoalveolar lavage from 27 healthy subjects in three groups of nine nonsmokers, light 
smokers, and heavy smokers, respectively. More than 3 times the number of macrophages 
were recovered from light smoker, and more than 8 times the number from heavy smoker 
lavage compared to lavage from nonsmokers. Zero of nine nonsmokers had iron greater than 
Pappas Page 16









the 10 ng/mL detection limit in lavage, whereas the mean iron concentration in light smoker 
lavage was 12.5 ng/mL, and in heavy smoker lavage was 49.7 ng/mL. The authors observed 
7.7 times higher ferritin in lavage from light smokers and 31.3 times higher in heavy 
smokers compared to nonsmokers.147 Thompson et al. found that both the bronchial and 
alveolar lavage extracellular and intracellular iron burdens of asymptomatic smokers and 
smokers with chronic bronchitis were very elevated compared with nonsmoking study 
participants.148 Moreno et al. illustrated the physiological redox availability of iron as a 
result of ferritin export from alveolar macrophages by demonstrating that aqueous extracts 
of cigarette smoke could reduce iron (III) and cause its release from ferritin.149 Boyer et al. 
modeled the role of the effects of polyhydroxy aromatic compounds in cigarette smoke by 
demonstrating that plant phenolics caused reduction and release of ferritin iron.150 The latter 
two studies demonstrated potentiation of iron availability for oxidation-reduction chemistry, 
supporting its role in generation of reactive hydroxide radical71 as part of the explanation for 
the lung oxidative stress and damage caused by smoking. Surface iron has also been shown 
to increase inflammatory response and increased production of reactive oxygen species from 
silica exposure in rat lung versus silica alone.74–77
The above findings on iron toxicology could be more revealing of the smoking-related lung 
pathology than superficially appears. Under proinflammatory cytokine stimulus, 
macrophages differentiate toward the M1 program and produce reactive nitrogen and 
oxygen species and additional proinflammatory cytokines such as IL-12, IL-23, and TNFα. 
Though chronic inflammation is a risk factor for carcinogenesis,151,152 the M1 phenotype 
mediates resistance to tumors and is characterized by increased expression of ferritin and 
suppression of expression of the iron exporter protein, ferroportin (Fpn), favoring 
sequestration of iron. Differentiation to the M2 phenotype occurs in response to T cell Th2 
cytokine IL-4, and is characterized by greater phagocytic activity, Fpn production and iron 
release, matrix deposition, tissue remodeling, and immunosuppression,153 which decreases 
resistance to tumors. There is rarely an all-or-none response in any regulated physiological 
system. Additional macrophage phenotypes have been noted, as well as phenotypes that are 
somewhat intermediate between the M1 and M2 subsets with characteristics of each.154 The 
finding of an increased number of alveolar macrophages in response to toxic insult from 
tobacco smoke particulate, and both increased intracellular and extracellular ferritin and free 
iron appears to be an indication that indeed, there is a combined response to particulate 
metals from both M1 and M2 or mixed macrophage subtypes. This is supported by the 
finding of both inflammatory response and elevated IgE in smokers as discussed earlier, and 
of immunosuppression discussed below.
Robbins et al. observed that exposure of mice to smoke from 4 unfiltered cigarettes per day 
decreased the numbers of dendritic cells in lungs, reduced maturation of dendritic cells and 
expression of MHCII in lymph nodes, and as a consequence, suppressed antigen-specific 
CD4+ T cell proliferation,155 as did Rossi et al. for “lymphocytes” in response to silica-
coated TiO2 particulate.132 Robbins et al. showed that cigarette smoke compromised 
antiviral immune responsiveness.140
Cozen et al. studied peripheral monocytic blood cell response to different intensities of 
chronic cigarette smoking between nonasthmatic monozygotic twins to eliminate genetic 
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factors related to atopy. They determined significant dose responses between heavy smokers 
(>20 cigarettes/day) and light smokers (<20 cigarettes/day) in monocyte production of IL-5 
(166% higher in heavy smokers) and IL-13 (146% higher in heavy smokers) but observed 
no significant differences in IL-4 production.156 These cytokines are more consistent with 
an increased Th2 type immune response in heavier smokers, with consequences that would 
be in accord with greater susceptibility to intracellular pathogens, as Yin et al. observed in 
response to heavy diesel exhaust particle exposure.133
In the first part of this section, the inflammatory burst-producing cytokine type response was 
emphasized, whereas in the latter part, discussion emphasizing sensitization, immunological 
suppression and alternative activation of macrophages was discussed. These roles are not in 
conflict, but are apparently a continuum of concurrent dose-dependent phenotypic activation 
and suppression. Basagaña et al. reported higher IgE production in smokers, but reported no 
significant correlations between elevated serum IgE, and atopy, maternal asthma, smoking, 
and occupational exposure. They described the lack of association between elevated IgE 
concentrations and atopic diseases as the “healthy smoker effect,”157 though their study 
population and data interpretation have been questioned.158
The findings of Shaykiev et al. and Thatcher et al. may better explain the reported findings 
of Basagaña et al.157 Shaykiev et al. observed that compared to healthy never-smokers, a 
relative suppression of the M1 inflammatory macrophage phenotype was associated with 
smoking, and that the progression toward M2-polarization was observed to increase with 
development of COPD in smokers.159 Thatcher et al. showed that high dose but not low 
dose mainstream cigarette smoke suppressed allergic airway inflammation in mice by 
inhibiting T cell function concurrently with reductions in eosinophilia, IL-4 and IL-5 
reductions in bronchoalveolar lavage, and loss of ovalbumin antigen-specific proliferation 
and cytokine production by T cells. The authors concluded that although smoking causes 
systemic inflammatory response, T cell-mediated responses involved in a number of 
diseases are inhibited by high-dose exposure to smoke.160 Although progression from M1 
fibrosis-initiating oxidative burst response towards sensitization-favoring M2 response 
appears to progress with dose or chronic exposure to smoke, the M2 response may also be 
suppressed as a result of loss of T cell function and suppression of IL-4 and IL-5 production. 
The net result immunologically appears to be initiation of a Th1/M1 inflammatory response 
with progression toward a more Th2/M2 IgE-producing and tumor-tolerant response but 
with concurrent suppression of the atopic inflammatory response typically associated with 
the Th2/M2 phenotypes. Ritter et al. found elevated concentrations of chemokine CCL17 
and CCL22 (Th2 cell chemoattractants) in both Th1 and Th2 rat inflammation models: 
smoke-induced inflammation and atopic asthma induced by ovalbumin sensitization. In spite 
of these elevated chemoattractants, the authors observed no increase in Th2 cell migration to 
smoke-exposed rat lungs.161 These findings may also help explain earlier data of Goel et al. 
in which reformed smokers showed significantly greater airways obstruction than current 
smokers.120 It may be that after cessation of smoking, the suppression of T cell function is 
relieved, permitting restoration of either or both of the Th1 inflammatory and Th2 
sensitization inflammatory responses. Since pulmonary particle accumulation from smoking 
requires many years to clear, the atopic or fibrotic consequences of exposure to 
bioaccumulated metals and silicates may continue to progress after smoking cessation.
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Nickel has been shown to dose-dependently suppress immune sensitization as described 
above. Wu et al. showed that mice with “very low” nickel exposure in diet alone could be 
sensitized to nickel with a single intradermal injection of 50 microliters 10 mM NiCl2. 
“Low” exposure mice could only be sensitized with 50 microliters 10 mM NiCl2 in the 
presence of an adjuvant. “High” exposure mice (chronic oral nickel-supplementation) were 
not sensitized with this procedure. The authors noted that this dose-dependent nickel 
tolerance correlated with differences in number and types of nickel-specific T regulatory 
lymphocytes.162 Thus some metals may exhibit adjuvant effects, or may be strongly 
sensitizing at low concentrations, whereas chronic exposure or possibly bioaccumulation as 
a result of chronic exposure may mediate antigen-specific immune suppression and resulting 
tolerance.
If this explanation was valid, then it would follow that suppression of the general innate 
(Th1/M1) immune response would manifest itself in less aggressive resistance to viral and 
microbial infections. Indeed, as discussed earlier, Yin et al. described the “aggravated” 
infection of rat with Listeria monocytogenes, after repeated low doses of diesel exhaust 
particulate with suppression of Th1 cell-mediated responses, and general downregulation of 
T cell responses on various days post-infection.136 Robbins et al. observed that chronic 
exposure of mice to smoke from 4 unfiltered cigarettes per day decreased the numbers of 
dendritic cells in lungs, reduced maturation of dendritic cells and expression of MHCII in 
lymph nodes, suppressed antigen-specific CD4+ T cell proliferation, and compromised 
antiviral immune responsiveness.155 Cortés et al. reported smoking as a risk factor second 
only to asthma for a severe case of H1N1 influenza requiring hospitalization during the 2009 
pandemic.163 Wu et al. reported that in human lung organ culture, cigarette smoke extract 
suppressed the retinoic acid-inducible gene I (RIG-I) initiated innate immune response to 
influenza virus as well as antiviral cytokine IFN-β.164 Feng et al. reported that exposure of 
mice to cigarette smoke for two hours twice a day, five days per week inhibited the T-Cell 
response to influenza virus and Mycobacterium tuberculosis.165 Arnson et al. have 
published an in depth review of effects, not specifically from inorganic, but from tobacco 
smoke on the immune system including discussion of suppression of both the innate and 
adaptive immune response.118 Thus, the data bears out the effects on the immune system as 
impacting both Th1/M1 and Th2/M2, innate and adaptive immune responses as well as 
impacting the number of cells recruited to the lungs.
Inflammation, sensitization, and pulmonary disease
Asthma is generally increasing in prevalence worldwide.166 Secondhand tobacco smoke has 
been associated with development of asthma in children.85,167,168 Gavet and Koren reported 
that environmental airborne particulate matter (PM) promoted allergic sensitization, 
increased allergic inflammation, and airway hyperresponsiveness. They reported also that 
exposure of human volunteers to emission source particulate matter samples that had been 
determined as having high concentrations of iron, nickel and vanadium increased indices of 
pulmonary oxidant formation. The increased indices of oxidant formation correlated with 
the quantity of transition metals in the samples. They concluded that PM samples with high 
concentrations of transition metals may enhance sensitization, promote formation of reactive 
oxygen species and subsequent lung injury, inflammation, and airway hyperresponsiveness 
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leading to airflow limitation and symptoms of asthma.169 Mutti et al. reported that median 
nickel concentrations in exhaled breath condensate was higher in asthmatics in their study 
than in controls and even than smokers who were not otherwise diagnosed with COPD.25 
These findings support the possibility of some of the same transition metals from tobacco 
smoke particulate as having a role in the same sensitization processes as environmental 
particulate.135 Thus metal sensitization must be considered as one of the mechanisms by 
which atopic asthma and possibly COPD (chronic bronchitis, chronic asthma, and 
emphysema) are initiated and progress, of course together with other sensitizing compounds 
such as polycyclic aromatic hydrocarbons. However, previous comments related to dose-
dependent immune suppression must also be considered. Exposure to secondhand smoke 
alone would not be expected to result in the same metalloparticle burden as inhalation of 
combined mainstream and sidestream smoke to which a smoker is exposed. As a result, the 
suppression of immune response observed in heavy smokers may not be a consequence of 
inhalation of secondhand smoke alone, given the discussion of decreased immune 
suppression in light smokers versus heavy smokers above.157,159,160 In the absence of 
suppression of the Th2/M2 response as a consequence of secondhand smoke exposure, 
atopic IgE-dependent responses included atopic asthma.
Willers et al. investigated associations between environmental tobacco smoke exposure, 
exposure to “heavy metals,” and nicotine (as the urine cotinine metabolite) in households of 
23 children with asthma. They found strong associations between the inquiry data-based 
tobacco smoke exposure index and urine cotinine, indicative of secondhand smoke 
inhalation. There were also strong associations between the latter two parameters and 
nicotine in house dust. Urine cadmium correlated well with urine cotinine, as did lead, 
though the correlation between cotinine and lead was not significant. The authors concluded 
that the children with asthma were being exposed to “heavy metals” from sidestream smoke 
via inhalation.167 An EPA-funded study of air quality in Baltimore city homes of asthmatic 
children showed that two percent of the PM10 values and seventeen percent of the PM2.5 
values exceeded the EPA's proposed National Ambient Air Quality Standards. The most 
important indoor contributor to high levels of indoor particulate matter was environmental 
tobacco smoke (ETS). Average PM2.5 and PM10 concentrations in nonsmoking households 
were respectively 25.8±14.9 and 37.7±18.8 μg/m3. Average PM2.5 and PM10 
concentrations in smoking households were respectively 59.1±42.5 and 71.2±46.7 μg/m3. 
This represented a 33 to 54 μg/m3 increase in PM concentrations in smoking households. It 
was determined that each cigarette smoked contributed approximately 1 μg/m3 of airborne 
particulate matter.170
Leikauf commented that complex mixtures including fine particulate matter and tobacco 
smoke are associated with respiratory symptoms and hospital admissions for asthma.85 
Leikauf further described hazardous air pollutant components of particulate matter as 
including “occupational asthmagens,” or components that act as adjuncts during 
sensitization.85 Once sensitized, an individual may respond to remarkably low 
concentrations of such compounds. Irritants may also lower the bronchoconstrictive 
threshold. Among the 33 hazardous air pollutants of greatest concern for exposure cited 
from U.S. Environmental Protection Agency reports, were compounds of metals described 
as suspected of inducing or exacerbating asthma: cadmium, chromium, manganese, and 
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nickel. Cobalt compounds were also listed as a hazardous air pollutant that can exacerbate or 
induce asthma, though it was not on the list of 33 compounds of greatest concern. Metallic 
mercury and mercury compounds were included on EPA's list of 33 compounds of greatest 
concern due to toxicity but were described as respiratory tract irritants that may exacerbate 
asthma rather than act as an inducer of asthma.85
Chronic Obstructive Pulmonary Disease (COPD) is increasing in prevalence worldwide. It is 
estimated that COPD in all forms will increase from the fourth leading cause of death in 
2004 to the third leading cause of death in 2030.171 As was the case for atopic asthma, 
allergic sensitization may also be associated with COPD. Itabashi et al. showed that though 
allergen skin test scores were higher in asthmatic patients than those with COPD, serum IgE 
was significantly higher in elderly COPD patients, as well as in asthmatic patients than in 
healthy subjects.172 Though asthma is classified as a distinct disease from COPD, some 
patients with asthma develop irreversible airway obstruction characteristic of COPD.173 
Pacheco et al. concluded that at least 17.6% of patients with emphysema associated with 
smoking had a clear asthmatic profile.174 Silva et al. further found active asthma as 
conferring a mean risk factor of 10 for developing chronic bronchitis, 17 for developing 
emphysema, and 12.5 for “fulfilling COPD criteria.”175 Jang et al. reported a study of 843 
asthmatic patients. Total IgE was higher in smokers than nonsmokers, but there was no 
significant difference in atopy. The prevalence of emphysema was higher among smokers; 
and asthmatic smokers with fixed airway obstruction were significantly higher than 
asthmatic nonsmokers.176
The projected increase in COPD is predominantly based on projected increases in tobacco 
consumption.171 Several metals, aluminum, cadmium, and lead have been reported at higher 
concentrations in the exhaled breath condensate of study subjects with Chronic Obstructive 
Pulmonary Disorder (COPD), than that of the nonsmoking healthy control subjects, as well 
as in current smokers vs. nonsmokers. Smoking COPD patients had significantly higher 
concentrations of several metals in exhaled breath condensate than ex-smokers and than 
nonsmokers with or without COPD,123 apparently due to smoking habits. The description of 
the pulmonary inflammatory cytokine environment described earlier as a consequence of 
metals or tobacco smoke particulate exposure is a fibrosis-potentiating cytokine 
environment. The role of metals in inflammation, sensitization, or in exacerbation of 
existing COPD thus warrants further study. Further investigation on relations between 
mainstream and sidestream smoke metals, potential for sensitization, inflammation, 
consequential development of atopic asthma and COPD, irritant-induced nonatopic 
bronchial hyperresponsiveness, and exacerbation of these diseases are needed.
Both asthma and COPD are inflammatory disorders. Feron et al. and Mueller have 
specifically described the risk of carcinogenesis resulting from chronic inflammation of 
various epithelial and mucosal tissues, without regard to whether the nature of the cause was 
irritant, allergic, or other.151,152 Thus the participations of various metals in the sensitization 
processes and inflammatory processes of asthma and COPD, or exacerbation of either 
disease pose carcinogenic risk beyond the immediate pulmonary pathology.
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Several of the metals discussed, especially those that are strongly inflammation-inducing 
and sensitizing, such as beryllium, chromium (VI), cobalt, nickel, silicates, and those which 
are toxic chemical irritants that possibly act by causing production of reactive oxygen 
species (copper, iron, manganese, silicates), are characterized as causing interstitial lung 
diseases when considered as occupational exposures.23 The concept of smoking-related 
interstitial lung disease (ILD, characterized by dyspnea, restrictive pulmonary function, 
impaired gas exchange, and diffuse lung eosinophilic edematous infiltrates) is relatively 
recent with regard to tobacco.177 Though the topic remains controversial, numerous authors 
have published on the clinical symptoms, underlying pathology, and radiological 
observations related to smoking-related interstitial lung disease. Selman lists smoking-
related diffuse interstitial lung disorders as including respiratory bronchiolitis-associated 
ILD, desquamative interstitial pneumonia, and pulmonary Langerhans cell histiocytosis. 
Selman described the symptomology and pathology as including dyspnea, cough, restrictive 
pulmonary function, bronchiole-centered lesions, interstitial and airspace inflammation, and 
fibrosis extending to the alveoli.178 Caminati and Harari further describe smoking-related 
ILD with regard to symptomology, smoking history, radiology, and pathology.179 Attili et 
al. presented radiological data describing the pathological manifestations of smoking-related 
ILD.180 Washko et al. reported that interstitial lung abnormalities were positively correlated 
with greater exposure to tobacco smoke and current smoking.181 Since metals and silicates 
independently of tobacco smoke in industrial exposures, environmental particulate 
exposures as described above cause sensitization, interstitial macrophage and dendritic cell 
migration and inflammation, increase in proteinaceous lavage, cough, restrictive pulmonary 
function, eosinophilic infiltrates, and may cause interstitial lung diseases, it is reasonable to 
consider possibilities of metal and silicate involvement in smoking-related interstitial lung 
diseases also. Corradi et al. reported that concentrations of silicon, nickel, copper, and iron 
in exhaled breath condensate were significantly higher from patients with idiopathic 
pulmonary fibrosis (13 of 19 were ex-smokers with a group mean of 24.5 pack-years) and 
non-specific interstitial pneumonia (10 of 15 were ex-smokers with a group mean of 26.4 
pack-years) than healthy non-smokers.182 Taskar and Coultas summarized the 
epidemiological evidence for causal relationships with idiopathic fibrotic lung diseases with 
the “strongest evidence for cigarette smoking and metal dust.”183 Miyake et al. reported 
significant mean odds ratios of 9.55 (metal dust exposure) and 3.23 (20.0 to 39.9 pack years 
of smoking) for development of idiopathic pulmonary fibrosis.184 More study should be 
devoted to metals and silicate involvement in smoking-related ILD and fibrotic disease in 
general.
As more and more information becomes available, it appears likely that the increasing 
number of non-cancer inflammatory and fibrotic lung diseases are associated with smoking 
in general and with metals exposure from smoking and other environmental sources. In 
some cases, the data on causes related to tobacco smoking overlaps the data on the same or 
similar diseases caused by the metals alone, or in particulate matter, including 
predominantly metals-containing environmental and tobacco smoke particulate matter. 
Chronic inflammatory response may, in turn, increase cancer risk.151,152
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Health Risks from Exposure to Metals in Smokeless Tobacco
Smokeless tobacco has been evaluated by the IARC as a group 1 carcinogen, which is to 
say, carcinogenic to humans beyond a reasonable doubt.185 Of the many harmful 
constituents in smokeless tobacco, potentially metals may constitute a significant health risk.
Toxic metal exposure from smokeless tobacco products and associated health risks have 
been studied to a very limited degree compared to particulate metal inhalation toxicology. 
The epithelial tissues of the oral cavity have high proximal transfer potential, which permits 
absorption and transfer of toxic metals from smokeless tobacco products across the 
epithelial tissue. Oral exposures are related to solubility in saliva and transfer by way of 
direct contact and absorption by oral mucosa. Systemic exposure likely occurs from direct 
oral absorption or from swallowed saliva or tobacco particulate in the digestive tract.
It is evident from dental studies that oral exposure to individual metals may have an impact 
on oral health. In particular, oral sensitization to cobalt, nickel, mercury, and other metals 
from dental materials has been shown to result in allergic contact inflammations, joint pain, 
positive allergic skin patch tests to the respective metals and other systemic manifestations 
in some individuals.186 Amini et al. have shown that nickel concentrations of oral mucosal 
cells of patients with fixed orthodontic appliances were significantly higher than those 
without the appliances, demonstrating that oral exposure to nickel was not only superficial, 
but by cellular absorption from saliva.187 Bolewska et al. reported that mucosal contact 
lesion mercury absorbed from dental amalgam was found predominantly in macrophage 
lysosomes.188 Though less work on toxicology from oral metals exposure from smokeless 
tobacco has been performed, leukoplakia and lichen planus lesions caused by metals alone 
or by smokeless tobacco are quite similar.
In order to estimate bioavailable or extraction efficiency for toxic and carcinogenic metals 
from smokeless tobacco, a few studies have reported concentrations of extractable toxic 
metals in artificial or human saliva. Unfortunately, there is not a standardized saliva 
formulation for tobacco extraction at the present time. Artificial saliva formulations used for 
extraction of toxic metals from tobacco have included 0.1 M phosphate buffer and EDTA, 
EDDHA, or DTPA;70 and saturated calcium phosphate, inorganic salts, sugars, enzymes, 
and mucin,31 the latter a closer approximation of natural saliva. Given sufficient extraction 
time, strong chelating agents almost quantitatively extract some toxic metals into solution 
from tobacco. The use of water alone or with added salts likely does not reflect saliva 
conditions. If phosphate is added without proteins and mucin, it may result in undetected 
metal extraction as a result of coprecipitation of insoluble phosphates when tobacco is 
centrifuged or filtered from the solution. Since mucin and protein functional groups are 
capable of chelating metals, a formula including these is more representative of metal 
bioavailability. Though a formula containing appropriate salts, saturated or supersaturated 
calcium phosphate, proteins and mucin better represents saliva conditions,31 the difficulty of 
preparation makes the use of saturated or supersaturated calcium phosphate an impractical 
component of a formula used for frequent analyses. A useful compromise formula might 
contain calcium and phosphate at 50% saturation to permit longer storage without 
precipitation.
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Kazi et al. reported significantly higher blood and scalp hair cadmium and lower zinc 
concentrations in male oral cancer patients than in “referent” subjects. They further reported 
that users of chewing tobacco with areca nut or betel quid had higher blood and scalp hair 
cadmium and lower zinc concentrations than those who did not use chewing tobacco.189 In a 
separate study, the same observations were reported for female mouth cancer patients versus 
“referents”. The same was true of tobacco smokers, for whom the cadmium/zinc ratios were 
even higher.190 Cadmium competes with zinc for biological binding sites. Elevated 
cadmium/zinc ratios have been associated with increased tendency for carcinogenesis. For 
example, Ogunlewe and Osegbe observed that serum and prostate tissue cadmium/zinc 
ratios in healthy control subjects and those with benign prostatic hypertrophy were always 
less than those in patients with prostate cancer,191 as was true in the Kazi et al. study of oral 
cancer.189 The Kazi et al. studies implicate oral absorption of cadmium from smokeless 
tobacco products in order to produce elevated blood and hair cadmium to zinc ratios in 
smokeless tobacco consumers. These studies were also examples of health risk from the 
impact of the cumulative absorption of a carcinogenic metal from smokeless tobacco or 
from tobacco smoke, whereas a one-time exposure alone (sometimes discussed and used as 
a means of minimizing health risk implications) would probably pose minimal risk.
An epidemiological study of arsenic-induced skin lesions in an area of Bangla Desh where 
well water has high arsenic concentrations showed that 157 women who chewed tobacco 
had significantly higher urine methylarsonic acid metabolite than 352 who did not use 
tobacco. Women with urine methylarsonic acid in the lowest tertile who used chewing 
tobacco had mean odds ratios of 3.8 for the arsenic-induced skin lesions versus those in the 
same tertile who did not use tobacco. Women with urine methylarsonic acid or inorganic 
arsenic in the highest tertile who used chewing tobacco had mean odds ratios of 7.3 and 7.5, 
respectively, compared to those in the same tertile who did not use chewing tobacco.192 
Although one could attribute arsenic from water as the principal etiologic factor for the skin 
lesions, smokeless tobacco products seemed to potentiate the occurrence of this endpoint.
Additional evidence to support a role for metals in oral inflammatory processes comes from 
changes in metallothionein concentration and distribution in oral mucosa with development 
of dysplasia that is characteristically observed with leukoplakia, and commonly observed as 
a consequence of smokeless tobacco use. Cellular metallothionein concentrations and 
metallothionein distributions from superficial to basal mucosal layers dramatically differ 
between non-dysplasic oral mucosa and moderate dysplasia observed with leukoplakia.193 
Under inflamed conditions, the oral mucosa apparently acts to protect itself from toxic 
metals that would bind to metallothionein. The risk of carcinogenesis resulting from chronic 
inflammation of various epithelial and mucosal tissues, without regard to whether the nature 
of the cause was irritant, allergic, or otherwise has been described.151,152 Whether from 
acute or chronic exposure to metals alone, or from metals together with other tobacco 
components, the chronic oral inflammations observed as a consequence of smokeless 
tobacco consumption pose health risks.
Some combination of irritants, toxins, and allergens from smokeless tobacco causes the 
contact inflammations observed as a consequence of smokeless tobacco use. Davis et al. 
describe the oral cavity as possessing a lining of highly vascular mucosa, parts of which are 
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uniquely sensitive to irritants because they can penetrate the tissue easily.194 Metal 
sensitization or toxicity resulting from exposure to metals extracted by saliva from tobacco 
held close to oral tissues may contribute to the hyperkeratosis, leukoplakia, erythroplakia, 
and other oral stomatitis inflammatory lesions observed as a consequence of smokeless 
tobacco use. Petro and Zhang examined murine T cells in whole splenic mononuclear cell 
populations and enriched T cells costimulated with anti-CD3 and anti-CD28 to enable 
activation in culture. They exposed the cells to 1/100 to 1/10,000 dilutions of centrifuged 
and sterile-filtered smokeless tobacco extract in cell culture medium. The results showed 
that T cell interferon-γ (IFN-γ) production was decreased at all dilutions of the extract, and 
that IL-10 was decreased after exposure to the 1/100 dilution. Decreased levels of IL-10 
relieves suppression of inflammmatory or sensitization responses. IL-2 production was 
increased after exposure to the 1/100 dilution.195 Proinflammatory IL-2 synthesized by T4+ 
helper (Th) lymphocytes is considered classically to promote proliferation of cytotoxic T 
lymphocytes and activation of B cells,196 and increases in IFN-γ production that selects for a 
predominantly Th1 (cell-mediated) lymphocyte response. However, the suppression of IFN-
γ may at the same time partially relieve regulatory counteraction of a Th2-mediated 
response.190 Interleukin-4 (IL-4) production was unaffected at any dilution. IL-4 is 
associated with induction of B cell class switching to IgE production, and increases in Major 
Histocompatibility Complex class II (MHCII) production. Thus the combined suppression of 
IL-10 and IFN-γ even under influence of elevated IL-2 synthesis, along with unsuppressed 
IL-4 and MHCII would imply enablement of a state of tissue inflammation and sensitization 
as a consequence of exposure to soluble tobacco extract, similar to that discussed for 
tobacco smoke particulate.
Summary
Sufficient evidence exists that suggest exposure to tobacco smoke via inhalation or from 
smokeless tobacco products via oral exposure result in significant uptake of many metals 
and metalloids. These exposures may have significant health ramifications including 
increased inflammatory and fibrotic lung diseases and cancers, oral inflammatory diseases 
and cancers, asthma, suppression of immune resistance, and possibly other pathological 
consequences not discussed in this review.
At present there are no large scale means for reducing the levels of metals in tobacco post 
harvest. Given the potential for significant health risk associated with metals, cessation is the 
only proven means to reduce health risks associated with metal and metalloid exposure from 
tobacco use. Cessation reduces but does not eliminate health risks from tobacco use. Thus, 
complete avoidance is preferable still. Tobacco products deliver a complex mixture of 
chemicals to the user. Reduction of a single class of potentially harmful constituents may not 
reduce overall risk. However, it seems that if reductions of harmful constituents are 
technically feasible, it would be prudent to do so.
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Metal concentration ranges reported in smokeless tobacco (μg/g tobacco)





As 0.108–0.256 0.143–0.437 0.1–3.5 0.13–0.29
Ba 110–203 38–158 3.1–19 (3%–21%)
Be 0.010–0.038 <0.003–0.010 (21%–32%)
Cd 1.06–1.11 0.30–1.09 0.1–3.1 0.73–1.58 0.66–1.88 0.302–0.508 (21%–47%) 5%–15% 81%–109%
Co 0.056–0.201 0.26–1.22 0.171–0.739 (30%–65%)
Cr 0.95–1.41 0.71–2.19 5.25–21.9 0.86–3.20




Ni 0.84–2.05 1.33–13.1 1.39–2.73 0.370–1.153 (30%–46%) 0%–2.5% 15%–64%
Pb 0.23–1.20 1.76–13 0.27–2.96 0.28–0.85 <0.13–0.153 (8%)
a
Extractable metals from smokeless tobacco (μg/g tobacco). Empty Spaces represent no reported analysis for the respective analyte.











Metal concentration ranges reported in cigarette tobacco (μg/g tobacco).
Citation Canada203 India201 Pakistan204 U.K.58 U.S.205 U.S.206
Al 431–782 699–1200
As 0.151 0.73–0.86 0.1–0.7 0.250–0.250
Ba 40.7–56.6 68.3–75.1
Be 0.016–0.017
Cd 0.930 0.28–0.87 2.2–4.5 0.5–0.8
Co <0.01–0.94 0.348–0.425
Cr 0.353 2.8–5.0 1.3–3.1 0.484–1.27




Ni 0.250 7.21–10.2 1.2–2.8 1.1–2.7 1.13–1.18
Pb 0.257 0.79–5.79 1.1–1.6 0.4–0.9 0.604–0.607
Empty Spaces represent no reported analysis for the respective analyte.

















Hammond ISO Canada203 Hammond Intense Canada203 Pappas U.S. ISO56
As <LOD-0.0055 <LOD-0.0145
Cd 0.0016–0.101 0.0435–0.1971 0.0576 0.1608 0.0138–0.0624
Hg 0.0011–0.0063 0.0042–0.0107 0.0032 0.0065
Pb 0.0039–0.0392 0.0257–0.0932 0.0167 0.0372 0.0071–0.0289











Inhalation Minimum Risk Levels derived from reviews of NOAELs and LOAELs reported in the literature. 
ATSDR cautions that criteria for reported calculations of some observed effect levels are based on serious 
disease and not appropriate for MRL calculations. In addition, ATSDR cautions that MRLs “…may not be 
protective for health effects that are delayed in development or are acquired following repeated acute insults, 
such as hypersensitivity reactions, asthma, or chronic bronchitis, such as discussed in this manuscript.” Where 





Cadmium39 0.01 mg m−3(>1 yr)
Chromium(VI)211 0.005 mg m−3(>1 yr)
Chromium(III)211 0.1 mg m−3 (15–364 days)




Manganese213 0.1 mg m−3 (>1 yr)
Mercury214 None
Silicates None
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